Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2018
Price : $35 *
At a glance
- Drugs Rotigotine (Primary)
- Indications Fibromyalgia; Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors UCB Pharma SA
- 01 Jul 2018 Results assessing PK, safety and tolerability from NCT01675024 and NCT02070796 trials published in the Clinical Therapeutics
- 28 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.